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A B S T R A C T
Urinary albumin is an important biomarker used to identify high risk patients with diabetes, but there is a need
for new biomarkers that alone or in combination with urinary albumin could give an even better prediction of
clinical patient outcomes. One promising biomarker is 8-oxo-7,8-dihydroguanosine (8-oxoGuo) that represents
intracellular oxidative stress. We investigated the ability of microalbuminuria (MA) and urinary 8-oxoGuo, alone
and in combination, to predict mortality and cardiovascular disease (CVD) in patients with type 2 diabetes.
We used data from 1381 newly diagnosed diabetes patients, and urinary albumin and 8-oxoGuo were assessed
in morning urine collected at the time of diabetes diagnosis and at a follow-up visit 6 years later. Associations
between the urinary markers and mortality and CVD were assessed in Cox proportional hazards regression
models. Test performance was assessed using sensitivity, speciﬁcity, positive predictive value and negative
predictive value for 10-year mortality and 10-year incidence of CVD.
Both 8-oxoGuo and urinary albumin were statistically signiﬁcantly associated with all-cause mortality at
diagnosis as well as at 6-year follow-up. At diagnosis only urinary albumin was associated with CVD. In contrast,
only 8-oxoGuo was associated with CVD at 6-year follow-up. When investigating test performance, we found that
by combining information from MA and 8-oxoGuo the ability to correctly identify patients at risk could be
improved.
The ﬁndings suggest that measurement of urinary 8-oxoGuo provides additional information about risk to
that obtained from urinary albumin, and that the combined use of 8-oxoGuo and urinary albumin could be useful
for a better identiﬁcation of patients at risk of CVD and death.
1. Introduction
Microalbuminuria (MA) is associated with an increased risk of
cardiovascular disease (CVD) [1], renal disease and death [2], and in
patients with type 2 diabetes (T2DM) MA correlates positively with the
degree of coronary atherosclerosis [3]. MA is caused by an increased
transglomerular passage of albumin and this passage is most likely
mediated by an increase in ﬁltration pressure and damage to the glo-
merular barrier. People with MA have an increased transcapillary es-
cape rate, which indicates that MA is not just a marker of renal injury
but also of systemic injury and dysfunction of the endothelium of the
blood vessels [4]. Furthermore, an increased transvascular lipoprotein
transport has been demonstrated in patients with T2DM and MA, which
could contribute to the formation of atherosclerosis [5]. The relation-
ship between MA and changes in the vessel wall is not yet fully un-
derstood, but there are several hypotheses, including destruction of the
glycocalyx on the surface of the glomerular endothelium [6], associa-
tion with inﬂammatory processes, endothelial dysfunction and platelet
activation [7].
Urinary albumin is an important biomarker used in the identiﬁca-
tion of high risk diabetes patients, but there is a need for new bio-
markers that alone or in combination with urinary albumin could give
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an even better prediction of clinical patient outcomes. New biomarkers
that can detect an accelerated rate of complications to T2DM earlier
than MA are warranted to ensure initiation of more aggressive treat-
ment regimens in high risk patients early in the natural history of the
disease [8,9]. One promising biomarker is the oxidative stress marker 8-
oxo-7,8-dihydroguanosine (8-oxoGuo) that represents intracellular
oxidative stress [10,11]. Oxidative stress is traditionally related to a
situation where the formation of reactive oxygen species exceeds the
capacity of an organism's antioxidant defense system. Furthermore, it is
now clear that changes in oxidative status have profound eﬀects on a
number of signaling and regulatory processes [12]. Oxidative stress is
thought to play a pivotal role in the development of diabetic compli-
cations, and several possible mechanisms have been suggested, in-
cluding increased formation of advanced glycation end products (A-
GEs), activation of protein kinase C and hexosamine pathways, and
damage to nucleic acids [13].
The RNA oxidation marker 8-oxoGuo is considered to be a product
of intracellular oxidative reactions. High urine concentrations of 8-
oxoGuo at diagnosis, 6 years later and an increase in this marker over
that period were associated with increased mortality in patients with
T2DM [10,11]. Whether the ability of 8-oxoGuo to identify patients
who are at high risk of complications is equal to or even greater than
that of urinary albumin is not known, and it is also not known if the
combined use of both biomarkers provides better prognostic informa-
tion. Because urinary albumin and 8-oxoGuo reﬂect diﬀerent patholo-
gical processes, the combined use could provide more information
compared with that obtained from a single biomarker.
In this study, we investigated the ability of MA and urinary 8-
oxoGuo, alone and in combination, to predict CVD and mortality in
patients with T2DM.
2. Methods
2.1. Study population
In the Diabetes Care in General Practice (DCGP) study [14], 474
general practitioners agreed to prospectively include all subjects on
their practice list who fulﬁlled the following criteria: newly diagnosed
diabetes based on hyperglycaemic symptoms and/or raised blood glu-
cose values, diagnosed between 1 March 1989 and 28 February 1992,
and aged 40 years or over. The diabetes diagnosis was subsequently
conﬁrmed with a single fasting whole blood/plasma glucose value of
≥7.0/8.0 mmol/l, measured at a major laboratory. The protocol-based
exclusion criteria were life-threatening somatic disease, severe mental
illness, or unwillingness to participate. Accordingly, 162 patients were
excluded and the study population consisted of 1381 newly diagnosed
diabetes patients. Based on the onset of insulin treatment within 180
days of diagnosis, approximately 97.5% were considered to have T2DM
[14]. One freshly voided morning urine sample was collected from all
patients at the time of diagnosis and on average 6 years later.
The protocol was approved by the ethics committee of Copenhagen
and Frederiksberg and informed consent was obtained from all patients.
2.2. Assessment of urinary markers and covariates
Urinary albumin and 8-oxoGuo were measured in a freshly voided
morning urine sample. Measurement of urinary albumin was done
using a polyethyleneglycol radioimmunoassay [15]. The frozen urine
samples were assayed between 2009 and 2010 for 8-oxoGuo using a
validated method of ultraperformance liquid chromatography (UPLC)
and tandem mass spectrometry [16]. Both urinary albumin and 8-ox-
oGuo were normalized against urinary creatinine concentration.
The assessment of the remaining patient characteristics at baseline
and at 6-year follow-up has been described elsewhere [14]. Cohabita-
tion status, education level and height (used in BMI calculation) were
only assessed at diagnosis.
2.3. Ascertainment of outcomes
Information on all-cause mortality and cardiovascular morbidity
was obtained from the Danish Civil Registration System, the Danish
National Patient Register, and the Danish Register of Causes of Death
[17–19]. The patients were followed up in these registers until 1 Jan-
uary 2009, for a total of 19 years after the diagnosis (or 13 years after
the 6-year assessment of the urinary markers). Cardiovascular mor-
bidity was deﬁned as incidence of a fatal or non-fatal myocardial in-
farction stroke, or peripheral vascular disease. The vital status of one
patient could not be assessed because this person had emigrated in
1992.
2.4. Statistical analysis
The characteristics of the patients at diagnosis and – for those that
were still in the study at that time point – at 6-year follow-up are shown
as median with inter-quartile range (IQR) for continuous character-
istics, or number with percentage for categorical characteristics. The
patients were categorized into four groups according to renal involve-
ment (MA, U-albumin/U-creatinine ≥ 2.5 mg/mmol) and oxidative
stress (U-8-oxoGuo/U-creatinine ≥ the median at diagnosis and 6-year
follow-up, respectively). Kaplan-Meier curves illustrate the mortality
and CVD incidence following diabetes diagnosis and 6-year follow-up
examination, respectively, for these four groups.
Associations between 8-oxoGuo and urinary albumin, and mortality
and CVD incidence were assessed in Cox proportional hazards regres-
sion models. These associations were estimated for the four-class vari-
able as described above, and by the continuously valued U-8-oxoGuo/
U-creatinine and U-albumin/U-creatinine variables, both separately
and jointly. For each association assessment two models were esti-
mated: a model only adjusted for age, sex and diabetes duration (for the
assessment at 6-year follow-up), and a second model further adjusted
for education, cohabitation status, smoking status, triglycerides, total
cholesterol, hypertension, hemoglobin A1c, serum creatinine, BMI,
physical activity, presence of retinopathy (yes/no) and CVD (yes/no) at
baseline (for analyses on mortality).
Sensitivity, speciﬁcity, positive predictive value (PPV) and negative
predictive value (NPV) were calculated for the above deﬁned dichot-
omisations of urinary albumin and 8-oxoGuo for 10-year mortality and
10-year occurrence of CVD. Reported p values were two-sided and
p<0.05 was considered to be signiﬁcant. Analyses were performed
with SAS version 9.4.
3. Results
3.1. Patient characteristics
Table 1 shows characteristics of the study participants. Data from
1.381 patients with newly diagnosed T2DM were included at baseline
and 970 participated in the 6-year follow-up. 312 patients died in the
period from baseline to 6-year follow-up. The median age (IQR) at di-
agnosis of was 65.4 (55.7–73.6) years, with a slight male pre-
ponderance (53%). The median age at 6-year follow-up was 69.2
(59.9–77.3) years, with an equal distribution of men and women
(51.4% and 48.6%, respectively). 31.7% had MA at diagnosis, and
34.7% had MA at 6-year follow-up. 4.3% and 5.4% had macro-
albuminuria (> 25 mg/mmol) at diagnosis and at 6-year follow-up,
respectively. The proportion of patients with retinopathy, peripheral
neuropathy and CVD increased from diagnosis to 6-year follow-up
(4.5–14.9%, 19.3–25.6%, 12.7–17%, respectively). At 6-year follow-up
57.5% were treated with oral antidiabetic drugs, 29.9% with diet alone
and 12.6% with insulin. Median HbA1c was 10.2% at diagnosis and
8.6% (reference interval: 5.4–7.4% at the time of the study) at 6-year
follow-up.
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3.2. Urinary 8-oxoGuo and albumin and risk of CVD and death
We identiﬁed a total of 966 deaths and 613 incident cardiovascular
events during the 19 years of follow-up.
Kaplan-Meier estimates of CVD and death for all subjects according
to the levels of urinary 8-oxoGuo (below or above median) and urinary
albumin (presence or absence of MA) are shown in Fig. 1 and Fig. 2. The
presence of MA and 8-oxoGuo above the median identiﬁed a group of
patients with a higher mortality and CVD morbidity compared with
patients without these risk factors, and patients that were risk marker
discordant (MA but 8-oxoGuo below median or no MA but 8-oxoGuo
above median) had intermediate risk.
These results were corroborated by the Cox regression analyses
where the combined categorical information of presence/absence of
MA and 8-oxoGuo above/below the median was robustly associated
with the outcomes independent of the covariates (Tables 2a and 2b).
The associations between urinary 8-oxoGuo and urinary albumin
and all-cause mortality and CVD were analyzed individually in re-
gression analyses, where 8-oxoGuo and albumin were included as
continuous variables (Tables 3a and 3b).
When assessed at diagnosis both 8-oxoGuo and urinary albumin
were associated with mortality (Table 3a). The multivariably adjusted
hazard ratios for all-cause mortality per unit increase in 8-oxoGuo and
urinary albumin were 1.68 (95% CI, 1.15–2.46; P = 0.007) and 1.03
(95% CI, 1.01–1.05; P = 0.005) respectively. The estimates were lar-
gely unchanged when both urinary albumin and 8-oxoGuo were in-
cluded in the models. Analyses using values of 8-oxoGuo and albumin
from 6-year after diagnosis yielded similar results (Table 3b). There was
an interaction between 8-oxoGuo and urinary albumin when assessed at
diagnosis in the age and sex adjusted model, but not in the multi-
variably adjusted model. There were no signiﬁcant interactions be-
tween 8-oxoGuo and urinary albumin assessed at 6-year follow-up.
At diagnosis urinary albumin was signiﬁcantly associated with CVD
(multivariably adjusted hazard ratio 1.04; 95% CI 1.03–1.06;
P<0.0001), while 8-oxoGuo from the same sample was not (Table 3a).
In contrast, 8-oxoGuo measured at 6-year follow-up was signiﬁcantly
associated with CVD (multivariably adjusted hazard ratio 1.53; 95% CI
1.21–1.94; P= 0.0004), while urinary albumin was not (Table 3b). The
estimates did not change much when both urinary albumin and 8-ox-
oGuo were included in the models. Regarding the risk for CVD, there
were no interactions between 8-oxoGuo and urinary albumin when
assessed at diagnosis. For values assessed at 6 years there was an in-
teraction between the terms in the age and sex adjusted model, but not
in the multivariably adjusted model.
Table 1
Characteristics of patients at diagnosis of type 2-diabetes and at 6-year follow-up.
At diabetes
diagnosis
At 6-year follow-
up
N 1381 970
U-albumin/U-creatinine (mg/mmol),
median (IQR)
1.30 (0.68–3.25) 1.55 (0.75–3.78)
Microalbuminuria (U-albumin/U-
creatinine ≥ 2.5 mg/mmol), n (%)
418 (31.7) 315 (34.7)
U-8-oxoGuo/U-creatinine (nmol/
mmol), median (IQR)
3.64 (2.86–4.77) 3.65 (2.94–4.66)
Age (years), median (IQR) 65.4 (55.7–73.6) 69.2 (59.9–77.3)
Male sex, n (%) 733 (53.1) 492 (50.7)
Diabetes duration (years), median (IQR) – 5.71 (5.01–6.32)
Basic education only, n (%) 1033 (78.8) 729 (78.1)
Living alone, n (%) 434 (32.2) 320 (35.4)
Smoking status, n (%)
Never 405 (30.1) 296 (33.0)
Previous 469 (34.8) 323 (36.0)
Current 472 (35.1) 278 (31.0)
Fasting triglycerides (mmol/L), median
(IQR)
1.98 (1.41–2.91) 1.80 (1.24–2.62)
Total cholesterol (mmol/L), median
(IQR)
6.2 (5.4–7.1) 6.0 (5.3–6.8)
Hypertension, n (%) 1026 (74.3) 709 (73.1)
Hemoglobin A1c (%), median (IQR) 10.2 (8.7–11.8) 8.6 (7.8–9.8)
Serum creatinine (µmol/L), median
(IQR)
89 (80–101) 90 (80–103)
BMI (kg/m2), median (IQR) 29.1 (26.1–32.7) 28.4 (25.5–32.0)
Physical activity, n (%)
Inactive 372 (27.7) 265 (29.6)
Active 973 (72.3) 630 (70.4)
Anti-diabetes treatment, n (%)
Diet only 290 (29.9)
Oral anti-diabetes treatment 557 (57.5)
Insulin 122 (12.6)
Retinopathy, n (%) 55 (4.5) 127 (14.9)
Peripheral neuropathy, n (%) 263 (19.3) 241 (25.6)
Cardiovascular disease, n (%) 176 (12.7) 164 (17.0)
Fig. 1. Kaplan–Meier estimates of incidence of CVD and death for all subjects according
to the levels of urinary 8-oxoGuo (below or above median) and albumin (presence or
absence of MA) at diabetes diagnosis. Both urinary albumin and 8-oxoGuo were nor-
malized against urinary creatinine concentration.
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3.3. Test performance for 10-year all-cause mortality and CVD
In Table 4 the ability of MA and 8-oxoGuo≥ median to predict 10-
year all-cause mortality and CVD is shown with the use of sensitivity,
speciﬁcity, PPV and NPV. For 10-year all-cause mortality and CVD the
speciﬁcity of MA was high (71.7–75.4%), both when assessed at diag-
nosis and at 6-year follow-up, meaning that absence of MA has a fair
ability to correctly identify those patients what will not develop CVD or
die within the next 10 years. In contrast, the ability of MA to correctly
identify those that will develop CVD or die within the next 10 years was
poor (sensitivity 38.2–45.0%).
When using the median of 8-oxoGuo as a cut-oﬀ, it was shown that
the sensitivity and speciﬁcity regarding 10-year all-cause mortality and
incidence of CVD were of the same magnitude, both when assessed at
diagnosis and at 6-year follow-up (sensitivity 52.1–58.9%, speciﬁcity
51.5–57.9%).
Combining MA and 8-oxoGuo ≥ median increased speciﬁcity
compared with MA alone (speciﬁcity 84.7–88.8%). Thus, absence of
MA plus 8-oxoGuo<median had a good ability to correctly identify
those patients that would not develop CVD or die within the following
10 years. In contrast, the ability of MA combined with 8-oxoGuo ≥
median to correctly identify those that will develop CVD or die within
the next 10 years was poor (sensitivity 20.8–28.0%). Compared to only
using MA to stratify the patients an increase in speciﬁcity was obtained
by combining MA and 8-oxoGuo, which was most pronounced for 10-
year all-cause mortality (speciﬁcity 75.4–87.3%) when markers were
assessed at diagnosis.
The PPVs in Table 4 are the probabilities of developing CVD or die
within the next 10 years when the test result was positive (MA was
present or 8-oxoGuo>median), and the NPVs are the probabilities of
not developing CVD or die within the next 10 years when the test was
negative.
These predictive values should be considered together with the
general 10-year incidence of CVD and death in the population (from
diagnosis: death 43.3%, CVD 32.8%; from 6-year follow-up: death
49.4%, CVD 37.8%). Thus, in this setting (in this population and with
an arbitrary 8-oxo-Guo≥ median cut oﬀ) both tests alone were clearly
better than chance to positively predict mortality (from diagnosis: 8-
oxoGuo PPV 50.7% and MA PPV 55.3% versus chance 43.3%; from 6-
year follow-up: 8-oxoGuo PPV 56.8% and MA PPV 61.9% versus chance
49.4%), and the combined test was rather convincingly able to predict
death (from diagnosis: PPV 61.8% versus chance 43.3%; from 6-years
follow-up: PPV 68.5% versus chance 49.4%). MA was slightly better
than 8-oxoGuo to predict the occurrence of CVD. The predictive power
of being alive 10 years after a negative test result was equally good for
MA and 8-oxoGuo, but the negative predictive power regarding CVD
was not substantially better than chance for any of the tests. Combining
the tests did not improve NPV.
Fig. 2. Kaplan–Meier estimates of incidence of CVD and death for all subjects according
to the levels of urinary 8-oxoGuo (below or above median) and albumin (presence or
absence of MA) at 6-year follow-up. Both urinary albumin and 8-oxoGuo were normalized
against urinary creatinine concentration.
Table 2a
Association of the combined categorical information of presence/absence of MA and 8-oxoGuo above/below the median at the time of diagnosis with 19-year mortality and CVD
morbidity among patients with T2DM.
Model 1 HR (95% CI) P value Model 2 HR (95% CI) P value
All-cause mortality
-MA, 8-oxoGuo<median 1.00 1.00
-MA, 8-oxoGuo>median 1.10 (0.92–1.31) 0.30 1.08 (0.88–1.32) 0.49
+MA, 8-oxoGuo<median 1.42 (1.15–1.74) 0.001 1.18 (0.92–1.52) 0.20
+MA, 8.oxoGuo>median 1.69 (1.39–2.05) < 0.0001 1.59 (1.27–1.99) < 0.0001
CVD
-MA, 8-oxoGuo<median 1.00 1.00
-MA, 8-oxoGuo>median 1.00 (0.80–1.25) 1.00 0.94 (0.72–1.23) 0.66
+MA, 8-oxoGuo<median 1.57 (1.22–2.03) 0.0005 1.33 (0.96–1.83) 0.082
+MA, 8.oxoGuo>median 1.63 (1.28–2.09) < 0.0001 1.50 (1.12–2.03) 0.007
Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, education, cohabitation status, smoking status, triglycerides, total cholesterol, hypertension, hemoglobin A1c, serum
creatinine, BMI, physical activity, presence of retinopathy (yes/no) and CVD at baseline (for analyses on mortality).
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4. Discussion
This is the ﬁrst study to investigate the combined use of the two
non-invasive biomarkers urinary albumin and urinary 8-oxoGuo for
identifying high risk patients with T2DM. We found that both MA and
urinary 8-oxoGuo individually were predictors of mortality in T2DM
patients, and when using them in combination the ability to identify
high-risk patients increased, indicating an added clinical value of 8-
oxoGuo as supplement to the present use of MA.
Our analyses showed that when analyzed individually in a Cox
proportional hazards regression analysis, both 8-oxoGuo and urinary
albumin were associated with all-cause mortality at diagnosis as well as
at 6-year follow-up. At diagnosis only urinary albumin was associated
with CVD. In contrast, only 8-oxoGuo was associated with CVD at 6-
year follow-up. Although this diﬀerence between the results at diag-
nosis and at follow-up could be a chance ﬁnding, it could also reﬂect
that some factors are important at the time of diagnosis, i.e. in the
untreated state, as opposed to the situation when the diabetes has been
present for 6 or more years with various treatments, among which
blockers of the renin-angiotensin system are frequently used and known
to reduce levels of urinary albumin [20]. Signiﬁcant interactions be-
tween 8-oxoGuo and urinary albumin were shown in the age and sex
adjusted models, but not in the multivariably adjusted models for all-
cause mortality at diagnosis and for CVD at 6-year follow-up. Thus, for
these analyses greater emphasis should be placed on the results derived
from the multivariably adjusted models.
Our results are in accordance with previous studies of diabetes pa-
tients that have found associations between albuminuria and incidence
of CVD and mortality [21–29]. The associations between urinary 8-
oxoGuo and CVD and mortality have so far only been investigated in
the present cohort. By using urinary 8-oxoGuo and urinary albumin
together the patients can be classiﬁed in risk categories according to the
combination of presence or absence of MA and high or low levels of 8-
oxoGuo. When investigating the sensitivity, speciﬁcity, PPV and NPV in
relation to 10-year mortality and 10-year CVD, we found that by
combining information on MA and 8-oxoGuo the ability to correctly
identify patients at risk could be increased.
Although the association between MA and mortality in type 2 dia-
betes is well-established [27,30,31], few studies have investigated test
performance of MA using sensitivity, speciﬁcity, PPV and NPV in the
prediction of CVD and death. In a study by Rutter et al., 86 patients
with T2DM (43 patients with MA (urinary albumin excretion rate>
10.5–200 g/min) individually matched with 43 normoalbuminuric
patients) the relationship between MA and future coronary heart dis-
ease was investigated [32]. Mean (SD) follow-up length was 2.5 (0.9)
years. The authors found the following test performance in the
Table 2b
Association of the combined categorical information of presence/absence of MA and 8-oxoGuo above/below the median at 6- year follow-up with 13 years mortality and CVD morbidity
among patients with T2DM.
Model 1 HR (95% CI) P value Model 2 HR (95% CI) P value
All-cause mortality
-MA, 8-oxoGuo<median 1.00 1.00
-MA, 8-oxoGuo>median 1.34 (1.09–1.67) 0.007 1.48 (1.14–1.92) 0.003
+MA, 8-oxoGuo<median 1.74 (1.37–2.22) < 0.0001 1.33 (0.97–1.83) 0.08
+MA, 8.oxoGuo>median 2.20 (1.70–2.84) < 0.0001 2.41 (1.77–3.28) < 0.0001
CVD
-MA, 8-oxoGuo<median 1.00 1.00
-MA, 8-oxoGuo>median 1.15 (0.90–1.47) 0.28 1.10 (0.81–1.49) 0.54
+MA, 8-oxoGuo<median 1.62 (1.18–2.23) 0.003 1.21 (0.81–1.81) 0.35
+MA, 8.oxoGuo>median 1.75 (1.29–2.37) 0.0003 1.71 (1.20–2.45) 0.003
Model 1: adjusted for age, sex and diabetes duration. Model 2: adjusted for age, sex, education, cohabitation status, smoking status, triglycerides, total cholesterol, hypertension,
hemoglobin A1c, serum creatinine, BMI, physical activity, presence of retinopathy (yes/no) and CVD at baseline (for analyses on mortality).
Table 3a
Relationship of urinary albumin and 8-oxoGuo with CVD and death.
(a) 19 years HR for the outcomes based on risk factor values at diagnosis.
Model 1 Model 2
HR (95% CI) p-value p-valuea HR (95% CI) p-value p-valuea
Death
Individually
Albumin 1.03 (1.02–1.04) < 0.0001 1.03 (1.01–1.05) 0.005
8-oxoGuo 1.26 (1.07–1.48) 0.005 1.68 (1.15–2.46) 0.007
Jointlyb
Albumin 1.03 (1.02–1.04) < 0.0001 <0.0001 1.03 (1.01–1.05) 0.004 0.08
8-oxoGuo 1.15 (0.97–1.37) 0.10 1.65 (1.09–2.51) 0.018
CVD
Individually
Albumin 1.03 (1.02–1.05) < 0.0001 1.04 (1.03–1.06) <0.0001
8-oxoGuo 1.39 (0.92–2.11) 0.12 1.27 (0.75–2.15) 0.38
Jointlyb
Albumin 1.03 (1.02–1.05) < 0.0001 0.98 1.04 (1.03–1.06) <0.0001 0.30
8-oxoGuo 1.35 (0.88–2.06) 0.16 1.24 (0.72–2.14) 0.43
Model 1: adjusted for age, sex and diabetes duration. Model 2: adjusted for age, sex, education, cohabitation status, smoking status, triglycerides, total cholesterol, hypertension,
hemoglobin A1c, serum creatinine, BMI, physical activity, presence of retinopathy (yes/no) and CVD at baseline (for analyses on mortality).
a For the interaction between 8-oxoGuo and urinary albumin.
b Both albumin and 8-oxoGuo are included in the model.
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prediction of coronary events: sensitivity: 78%, speciﬁcity: 53%, PPV:
16%, and NPV: 95%. This is in contrast to our study that for 10-year
occurrence of CVD showed higher speciﬁcities than sensitivities.
However, these values are not directly comparable with our results due
to the diﬀerent selection of participants. Furthermore the diﬀerences
may be explained by the diﬀerent deﬁnition and cut-point for MA,
diﬀerent deﬁnition of outcome, and diﬀerence in length of follow-up-
period and incidence of outcomes in the two populations.
The use of test performance measures in cross-sectional designs, for
instance to diagnose an infectious condition, often yields higher values
of speciﬁcity, sensitivity, PPV and NPV than we found in the present
study. Of note, few tests use these measures to predict long term out-
comes, and it is notoriously diﬃcult to reliably predict future mortality
and morbidity. MA is widely used in clinical work despite its seemingly
modest predictive power, and 8-oxoGuo may well prove to be equally
good and perhaps better than MA to predict long term outcomes if a
more optimal cut-oﬀ value is identiﬁed. However, ﬁne tuning of cut-oﬀ
values was beyond the scope of this article. We used an arbitrary ≥
median 8-oxoGuo, and future research must further explore in this ﬁeld.
An important limitation in this study is the reliance on a single
measurement of the albumin and 8-oxoGuo in a morning spot urine
sample. Glucose variability, which has been shown to exhibit a more
speciﬁc triggering eﬀect on oxidative stress than chronic sustained
hyperglycemia [33,34], was not assessed in the study. In addition, the
potential impact of diﬀerent treatment options on urinary albumin and
8-oxoGuo excretion was not determined. Finally, the lack of informa-
tion on diet, for example on the consumption of antioxidants, which
potentially could aﬀect the level of oxidative stress, should be men-
tioned. The main strengths of our study include the large and popula-
tion-based patient sample, the prospective design, the long follow-up
period, and the low attrition rate.
As pointed out above, the exact mechanism underlying the asso-
ciation between albuminuria and CVD and death is unknown. This is
also the case for 8-oxoGuo, but we have hypothesized that the oxidation
of mRNA, rRNA, tRNA could aﬀect the translational process negatively,
leading to smaller quantities of protein overall and/or defective pro-
teins, which may have detrimental eﬀects on a variety of distinct cel-
lular processes that lead to changes in proliferation and apoptosis and
eventually the development of the atherosclerotic plaque [10]. Through
this pathway increased RNA oxidation may be involved in the
Table 3b
Relationship of urinary albumin and 8-oxoGuo with CVD and death.
(b) 13 years HR for the outcomes based on risk factor values measured 6 years after diagnosis.
Model 1 Model 2
HR (95% CI) p-value p-valuea HR (95% CI) p-value p-valuea
Death
Individually
Albumin 1.04 (1.02–1.07) 0.001 1.04 (1.00–1.08) 0.03
8-oxoGuo 1.71 (1.30–2.26) 0.0001 1.79 (1.34–2.38) <0.0001
Jointlyb
Albumin 1.04 (1.01–1.06) 0.003 1.00 1.03 (1.00–1.07) 0.08 0.06
8-oxoGuo 1.60 (1.24–2.07) 0.0003 1.66 (1.26–2.18) 0.0003
CVD
Individually
Albumin 1.03 (1.00–1.06) 0.09 1.03 (0.98–1.09) 0.28
8-oxoGuo 1.52 (1.21–1.92) 0.0004 1.53 (1.21–1.94) 0.0004
Jointlyb
Albumin 1.03 (1.00–1.06) 0.10 0.007 1.03 (0.97–1.08) 0.35 0.41
8-oxoGuo 1.41 (1.14–1.75) 0.002 1.38 (1.08–1.77) 0.01
Model 1: adjusted for age, sex and diabetes duration. Model 2: adjusted for age, sex, education, cohabitation status, smoking status, triglycerides, total cholesterol, hypertension,
hemoglobin A1c, serum creatinine, BMI, physical activity, presence of retinopathy (yes/no) and CVD at baseline (for analyses on mortality).
a For the interaction between 8-oxoGuo and urinary albumin.
b Both albumin and 8-oxoGuo are included in the model.
Table 4
Test performance of MA and 8-oxoGuo>median in patients with T2DM.
At diagnosis:
MA High 8-oxoGuo MA AND high 8-oxoGuo
Sens Spec PPV NPV Sens Spec PPV NPV Sens Spec PPV NPV
10 year 41.6% 75.4% 55.3% 63.9% 58.9% 56.9% 50.7% 64.8% 28.0% 87.3% 61.8% 62.4%
All-cause mortality
10 year CVD 39.7% 73.4% 41.8% 71.7% 53.1% 52.3% 35.2% 69.6% 25.3% 84.8% 44.6% 70.2%
At 6-year follow-up:
MA High 8-oxoGuo MA AND high 8-oxoGuo
Sens Spec PPV NPV Sens Spec PPV NPV Sens Spec PPV NPV
10 year 45.0% 74.7% 61.9% 59.8% 58.3% 57.9% 56.8% 59.4% 26.8% 88.8% 68.5% 57.2%
All-cause mortality
10 year CVD 38.2% 71.7% 43.9% 66.7% 52.1% 51.5% 39.4% 63.9% 20.8% 84.7% 44.2% 64.8%
Sensitivity, speciﬁcity, positive predictive value (PPV) and negative predictive value (NPV) of MA and 8-oxoGuo>median for 10-year mortality and 10-year occurrence of CVD.
K. Broedbaek et al. Redox Biology 13 (2017) 363–369
368
development of the vascular complications in diabetes.
In this study, both 8-oxoGuo and albuminuria were independent
risk factors for mortality. Thus, both tests hold information about pa-
thological processes beyond age, sex, comorbidity and the other cov-
ariates included in the multivariably adjusted model. We hypothesize
that urinary albumin and 8-oxoGuo are proxy measures of diﬀerent
mechanisms involved in the development of complications, and by
combining the two markers, we can get a more diﬀerentiated picture of
the deteriorating processes that, if untreated, eventually will lead to
overt CVD and death. The ﬁndings in this study suggest that measure-
ment of urinary 8-oxoGuo provides additional information about risk to
that obtained from urinary albumin, and that the combined use of the
non-invasive biomarkers urinary 8-oxoGuo and urinary albumin could
be useful for a better identiﬁcation of patients at risk of CVD and death.
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